阿立哌唑与氯丙嗪治疗精神分裂症对照研究

Contrastive Study of the Treatment of Schizophrenia with Aripiprazole and Chlorpromazine

目的:比较阿立哌唑与氯丙嗪治疗精神分裂症的临床疗效与安全性。方法:将精神分裂症患者100例随机分为阿立哌唑组与氯丙嗪组,治疗12周。采用阳性与阴性症状量表(PANSS)及治疗中出现的症状量表(TESS)、健康状况问卷(SF-36)评定疗效及不良反应。结果:两组治疗后PANSS评分均显著下降,两组间比较差异无显著性(P>0.05)。不良反应发生率阿立哌唑组显著低于氯丙嗪组(P<0.05)。结论:阿立哌唑治疗精神分裂症疗效与氯丙嗪相仿,不良反应少,是一种安全有效的抗精神病药。

Objective： To compare the clinical efficacy and safety between aripiprazole and chlorpromazine in the treatment of schizophrenia. Method： 100 patinents with schizophrenia were randomly divided into two groups, aripiprazole group and chlorpromazine group for 12 weeks. The positive and negative symptom scale （ PANSS ） , treatment emergent symptom scale （TESS） , and short form 36 health survey questionnaires （SF-36） were used to evaluate the efficacy and safety. Result： The total scores of PANSS obviously decreased in both groups and there was no significant difference between the two groups after the treatment（ P 〉 0.05 ）. The incidence rate of side effects in the aripiprazole group was significantly lower than that in the chlorpromazine group （ P 〈 0.05 ）. Conclusion ： Aripiprazole has its similar efficacy to chlorpromazine and fewer side effects in the treatment of schizophrenia and, therefore, is a safe and effective antipsychotic drug.